2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
Disclosed herein are 2′-spiro-nucleosides and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus.
1. A method of treating a hepatitis C virus infection in a subject in need thereof, comprising administering to the subject an effective amount of the compound:
or a stereoisomer, salt, metabolite or deuteride thereof.
2. The method of claim 1 , wherein the hepatitis C virus is of genotype 1b.
3. The method of claim 1 , wherein the compound is administered by suppository administration.
4. The method of claim 1 , wherein the compound is administered orally.
5. The method of claim 4 , wherein the compound is administered in the form of a tablet, capsule, solution, emulsion, syrup or a suspension.
6. The method of claim 4 , wherein the compound is administered at a daily dosage of from about 0.01 gm to about 1 gm.
7. The method of claim 1 , wherein the method further comprises administering an effective amount of another antiviral agent.
8. The method of claim 7 , wherein the another antiviral agent is a NS3 protease inhibitor, NS4 inhibitor, NS5A inhibitor or NS5B inhibitor.
9. The method of claim 8 , wherein the another antiviral agent is a NS3 protease inhibitor.
10. The method of claim 7 , wherein the compound and the another antiviral agent are formulated in same dosage form or separate dosage forms.
11. The method of claim 7 , wherein the administering of the compound and the another antiviral agent is concurrent or alternative.
12. A method of treating a hepatitis C virus infection in a subject in need thereof, comprising administering to the subject an effective amount of the compound:
or a stereoisomer, salt, metabolite or deuteride thereof.
13. The method of claim 12 , wherein the hepatitis C virus is of genotype 1b.
14. The method of claim 12 , wherein the compound is administered by suppository administration.
15. The method of claim 12 , wherein the compound is administered orally.
16. The method of claim 15 , wherein the compound is administered in the form of a tablet, capsule, solution, emulsion, syrup or a suspension.
17. The method of claim 15 , wherein the compound is administered at a daily dosage of from about 0.01 gm to about 1 gm.
18. The method of claim 12 , wherein the method further comprises administering an effective amount of another antiviral agent.
19. The method of claim 18 , wherein the another antiviral agent is a NS3 protease inhibitor, NS4 inhibitor, NS5A inhibitor or NS5B inhibitor.
20. The method of claim 19 , wherein the another antiviral agent is a NS3 protease inhibitor.
21. The method of claim 18 , wherein the compound and the another antiviral agent are formulated in same dosage form or separate dosage forms.
22. The method of claim 18 , wherein the administering of the compound and the another antiviral agent is concurrent or alternative.
23. A method of treating a dengue virus infection in a subject in need thereof, comprising administering to the subject an effective amount of the compound:
or a stereoisomer, salt, metabolite or deuteride thereof.
24. The method of claim 23 , wherein the compound is administered by suppository administration.
25. The method of claim 23 , wherein the compound is administered orally.
26. The method of claim 25 , wherein the compound is administered in the form of a tablet, capsule, solution, emulsion, syrup or a suspension.
27. The method of claim 25 , wherein the compound is administered at a daily dosage of from about 0.01 gm to about 1 gm.
28. The method of claim 23 , wherein the method further comprises administering an effective amount of another antiviral agent.
29. The method of claim 28 , wherein the compound and the another antiviral agent are formulated in same dosage form or separate dosage forms.
30. The method of claim 28 , wherein the administering of the compound and the another antiviral agent is concurrent or alternative.
31. A method of treating a dengue virus infection in a subject in need thereof, comprising administering to the subject an effective amount of the compound:
or a stereoisomer, salt, metabolite or deuteride thereof.
32. The method of claim 31 , wherein the compound is administered by suppository administration.
33. The method of claim 31 , wherein the compound is administered orally.
34. The method of claim 33 , wherein the compound is administered in the form of a tablet, capsule, solution, emulsion, syrup or a suspension.
35. The method of claim 33 , wherein the compound is administered at a daily dosage of from about 0.01 gm to about 1 gm.
36. The method of claim 31 , wherein the method further comprises administering an effective amount of another antiviral agent.
37. The method of claim 36 , wherein the compound and the another antiviral agent are formulated in same dosage form or separate dosage forms.
38. The method of claim 36 , wherein the administering of the compound and the another antiviral agent is concurrent or alternative.
39. A compound of formula:
or a stereoisomer, salt, metabolite or deuteride thereof.
40. A compound of formula:
or a stereoisomer, salt, metabolite or deuteride thereof.